MedTrace Logo

Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples

NCT04391647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-09-29

No results posted yet for this study

Summary

The main objective of this study is to develop protocols using FV urine that investigate in vitro whether infectious virions can be neutralized by HPV vaccination.

Conditions

  • Human Papilloma Virus Infection

Interventions

OTHER

First-void urine collection

* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination. * IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)

OTHER

Blood draw

\- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.

Sponsors & Collaborators

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Pierre Van Damme, Prof, MD, PhD · Universiteit Antwerpen

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2020-07-01
Completion
2020-07-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391647 on ClinicalTrials.gov